Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Bladder Carcinoma

In brief

This randomized phase II/III trial studies gabapentin in reducing the need for pain medication in patients with bladder cancer undergoing surgery to remove the bladder and nearby tissue and organs. Gabapentin may reduce the amount of pain medicine required after surgery, improve pain after surgery, and/or reduce the length of hospital stay after surgery.

Key facts

Study ID

NCT02355886

Run by

University of Washington

People needed

25

Starts

2015-04-22

Expected to finish

2019-02-28

Last updated by the study team

2019-06-04

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of bladder cancer
• Anticipated radical cystectomy with ileal conduit or orthotopic neobladder

You may not qualify if…

• Presence of spinal cord injury including any form of paraplegia or quadriplegia
• Allergy to gabapentin
• Active alcohol dependence, defined as 2 or more positive questions on the CAGE alcoholism questionnaire
• Illicit drug use (excluding recreational marijuana)
• Chronic kidney disease with glomerular filtration rate < 30 ml/min
• Pregnancy: All female patients < 55 years old (yo) will be administered a urine pregnancy test prior to enrollment
• Non-English speaking patients
• Chronic gabapentin, or the similar drug pregabalin, use
• Chronic narcotic use (daily or near daily use for > 90 days)

Where it is running

• Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.